In October, 2018, the International Union Against Tuberculosis and Lung Disease (The Union) and The World Diabetes Foundation released the first edition of new guidelines pertaining to the treatment of patients with concurrent tuberculosis and diabetes. "These are the first global guidelines on how to screen for and manage people with diabetes-tuberculosis...They are holistic and also include advice about infection control in diabetes clinics, recording and reporting, and about how to set up joint collaboration in the ministries of health", says Anthony Harries (The Union, London, UK).
These guidelines state that patients with newly diagnosed diabetes should be systematically screened for tuberculosis in countries with a high burden of the disease, where prevalence is greater than 100 cases per 100 000 patients. Likewise, they state that all patients with tuberculosis should be screened for diabetes. "Clinical research still needs to be conducted to identify which subgroup of patients are at risk for progressing from temporary tuberculosis-induced hyper glycaemia to diabetes, and therefore stand to profit from a more regular follow-up", states Sonia Menon (Ghent University, Ghent, Belgium). If screening is done only once, there is also a dilemma concerning its timing. It would be much simpler to screen all patients with tuberculosis for diabetes at the time of diagnosis, "although it should be borne in mind that stress-induced hyperglycaemia in previously undiagnosed diabetes in most cases is temporary and would therefore undoubtedly result in overtreatment of a large number of patients with false-positive results", explains Menon. Conversely, if the screening is done at a later stage during tuberculosis treatment, the number of false-positive results should be minimised. "It is likely that individuals with transient hyperglycaemia during tuberculosis are at increased lifetime risk for progression to sustained diabetes, but the magnitude of that risk is currently unknown", says Hardy Kornfeld (University of Massachussetts, MA, USA).
Metformin remains the first-line drug for treatment of diabetes in patients with tuberculosis, and may be associated with the best treatment outcomes. "The reasons are unclear, but metformin does seem, in the laboratory, to have anti-tuberculosis effects", says Harries. Treatment failure and recurrence of tuberculosis are more common in patients with diabetes. "Recommendations for similar tuberculosis treatment in individuals with or without diabetes are reasonable based on limited evidence, but given the increased risk for recurrence, a case can be made for extended surveillance after tuberculosis treatment completion in individuals with diabetes", says Kornfeld. "Research has also shown that there is a positive association between diabetes and drug-resistant tuberculosis", states Harries. The reasons are unclear, but possibly include high initial bacterial loads, slow responses to treatment, poor infection control measures in clinics, high susceptibility to drug-resistant tuberculosis, and high chances of failing treatment, which increases the risk of drug resistance.
There are some unique challenges in the management of tuberculosis in these patients, including an increased risk of death, failure of anti-tuberculosis treatment, and recurrent disease once treatment is complete. Additionally, patients with diabetes might present atypically with tuberculosis, making diagnosis more difficult. "Patients have to take drugs for diabetes and for tuberculosis and therefore there is a higher pill burden; there are drugdrug interactions which make the choice of diabetic drugs difficult, and there are overlapping drug toxicities which need to be monitored", says Harries. Another important issue in managing tuberculosis is infection control. The Union recommends that patients with concurrent diabetes and tuberculosis should preferably be managed in the tuberculosis clinic only for the first 2 months, and visits to the diabetes clinic should be avoided to prevent transmission of infection to other susceptible patients and health-care workers. For complicated cases, consultants from diabetes clinics can provide recommendations for patients being seen in tuberculosis clinics, either by phone, electronically, or in person. "Diabetes clinics currently have no systems for infection control yet; this is crucially important if patients have tuberculosis", says Harries.
Counselling on lifestyle modification, such as smoking cessation, physical activity, and diet, is also recommended in patients with concurrent diabetes and tuberculosis. The Union also recommends offering low-dose aspirin and a statin to people with diabetes and cardiovascular disease. Cardiovascular risk factors such as smoking, obesity, excessive alcohol consumption, hypertension, and hyperlipidaemia have special considerations in patients with tuberculosis. For example, while addressing obesity, providers must note that patients often gain weight as a result of tuberculosis treatment. Alcohol and antituberculous drugs together can increase the risk of liver dysfunction. Furthermore, rifampicin reduces the efficacy of some anti-hypertensives and most statins.
These recommendations are reasonable but are "challenged by adherence and lacking data to predict the magnitude of beneficial effect", comments Kornfeld. Clinicians need to better understand the causes of death in people with concurrent diabetes and tuberculosis. "If, for example, many people die from diabetes-related cardiovascular disease, we need to step up our advice about aspirin and statins and cardiovascular risk management", says Harries. 
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